Media and Press Center

Wilmington, NC:  AAIPharma announces that it has acquired the Xcelodose® 600S system; the most advanced and accurate capsule filling equipment available to the pharmaceutical industry.  With the Xcelodose® 600S, manufacturing clinical trial materials has become faster and more precise, and will enhance AAIPharma’s capability to rapidly supply preclinical and early phase clinical GMP supplies.

CEDAR KNOLLS, NJ and WILMINGTON, NC, April 6, 2009 – Emisphere Technologies, Inc. (NASDAQ: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and nutritional supplements using its Eligen® Technology, and AAIPharma, Inc. announce a strategic alliance intended to expand the application of Emisphere’ s Eligen® Technology and AAIPharma’s drug development services.

eResearchTechnology, Inc. (ERT), and AAIPharma have entered an alliance to provide integrated Cardiac Safety and Clinical Pharmacology Contract Research Services to clinical researchers worldwide. Culturally, both organizations are aligned in market approach, scientific excellence, quality and client satisfaction.

Press Release
FOR IMMEDIATE RELEASE

AAIPharma and CORTRIA Corporation Sign Drug Delivery Deal

 
CORTRIA Granted Exclusive License to Apply ProCR Technology to TRIA-662

WILMINGTON, NC and BOSTON, Mass. - December 15, 2008 -- AAIPharma and CORTRIA Corporation today announced they have signed a deal granting CORTRIA Corporation the right to use AAIPharma's proprietary, controlled release oral drug delivery technology known as ProCR in conjunction with CORTRIA's TRIA-662 drug candidate.

For the complete press release click on this link. http://www.scolr.com/news/?p=195

Stephen Turner, the Company's Chief Technical Officer, commented, "We are extremely pleased with these critically important results. In addition to the primary outcomes, we also achieved important secondary endpoints, including confirmed single dose onset of pain relief within one hour of the first dose, and then maintained efficacy over the full twelve hours following the patients' dental surgery."

DATELINE (November 10, 2008) - AAIPharma, a global provider of drug development services, today announced the appointment of Andreas Dreps, Ph.D., as Senior Vice President, Global Clinical Development Services. In addition, the company also announced that Ralf Wolter, Ph.D., has joined as Vice President Clinical Operations Europe reporting to Dr. Dreps.

September 17, 2008

 
Ron Kershner, Ph.D., vice president of biostatistics and data management at AAIPharma, will present The Role of the Data Monitoring Committee (DMC), during the Society of Clinical Research Associates Annual Conference in Vancouver, BC.

AAIPharma announces the appointment of Scott Neilson to the position of Chief Operating Officer. Mr. Neilson will be responsible for AAIPharma's global drug development services operations reporting to Dr. Ludo Reynders, Chief Executive Officer and President.

Ronald Kershner joins AAIPharma to lead the Company's North American Biostatistics and Data Management Services groups. Ronald brings over 25 years of industry experience at various large pharmaceutical, biotechnology and Contract Research companies. In previous roles with inVentiv, Inveresk and Omnicare, Ronald was responsible for the oversight of biostatistics and data management across a variety of therapeutic areas. Ronald brings significant experience with regulatory submissions and FDA interactions and has been involved in over 20 NDA submissions.

AAIPharma has received its second certification from a European Union (EU) regulatory body that the company's operations are in compliance with EU Good Manufacturing Practice (GMP) regulations. Following an audit of AAIPharma's manufacturing, testing and stability operations located in Wilmington, North Carolina, USA, Sweden's Medical Products Agency (MPA) notified the company that tablet, capsule and other solid dose drug manufacturing and testing operations can be certified as meeting EU GMPs.